drug · small molecule
ribociclib succinate
Marketedupdated 5mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.
targets
Cyclin-dependent kinase 4Cyclin-dependent kinase 6
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 17, 2027
348 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Apr 14, 2036formulationUS 10799506
- Apr 14, 2036formulationUS 12064434
- Apr 14, 2036formulationUS 12419894
- Aug 7, 2034method-of-use (U-3975)US 12544379
- Aug 7, 2034method-of-use (U-4405)US 12544380
- Nov 9, 2031compositionUS 9193732
- Nov 9, 2031method-of-use (U-3266)US 9868739
- Mar 13, 2031compositionUS 84153554.4y
- May 25, 2030compositionUS 86859803.6y
- Dec 9, 2029method-of-use (U-3975)US 89626303.2y
- Aug 20, 2029method-of-use (U-3975)US 94161362.9y
- Jun 17, 2028compositionUS 83242251.7y
FDA exclusivities (1)
- Sep 17, 2027I-950Indication (3y)348d
News(6)
- AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger marketSERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.biospace · 19d ago
- Novartis’ board faces investor scrutiny after M&A misfires and R&D flopsBack-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.biospace · 22d ago
- AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerThe approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…biospace · 25d ago
- Novartis climbs on upbeat drug sales as key readouts loomA return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.biopharma_dive · 2mo ago
- Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsNovartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…biospace · 2mo ago
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 4mo ago
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that